Running Title: Role of Cbl mutations in myeloid transformation

Abstract In acute myeloid leukemia (AML), mutational activation of the receptor tyrosine kinase (RTK) Flt3 is frequently involved in leukemic transformation. However, little is known about a possible role of highly expressed wild-type Flt3 in AML. The proto-oncogene c-Cbl is an important regulator of RTK signaling, acting through its ubiquitin ligase activity and as a platform for several signaling adaptor molecules. Here, we analyzed the role of c-Cbl in Flt3 signal transduction and myeloid transformation. C-Cbl physically interacted with Flt3 and was tyrosine phosphorylated in the presence of Flt3-ligand (FL). Overexpression of a dominant negative form of c-Cbl (Cbl-70Z) inhibited FL-induced Flt3 ubiquitylation and internalization, indicating involvement of c-Cbl in Flt3 signaling. DNA sequencing of AML bone marrow revealed a case with a c-Cbl point mutation (Cbl-R420Q). Cbl-R420Q inhibited Flt3 internalization and ubiquitylation. Co-expression of Cbl-R420Q or Cbl-70Z with Flt3 induced cytokine-independent growth and survival of 32Dcl3 cells in the absence of FL. Also, the mutant Cbl proteins altered the amplitude and duration of Flt3-dependent signaling events. Our results indicate an important role of Cbl proteins in Flt3 signal modulation. Also, the data suggest a novel mechanism of leukemic transformation in AML by mutational inactivation of negative RTK regulators. From bloodjournal.hematologylibrary.org by guest on June 6, 2013. For personal use only.

[1]  J. Schlessinger,et al.  Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.

[2]  A. Tsygankov,et al.  The Cbl family proteins: Ring leaders in regulation of cell signaling , 2006, Journal of cellular physiology.

[3]  H. Boswell,et al.  Constitutive c-jun N-terminal kinase activity in acute myeloid leukemia derives from Flt3 and affects survival and proliferation. , 2006, Experimental hematology.

[4]  E. Heiss,et al.  Direct binding of Cbl to Tyr568 and Tyr936 of the stem cell factor receptor/c-Kit is required for ligand-induced ubiquitination, internalization and degradation. , 2006, The Biochemical journal.

[5]  Dan Baird,et al.  Cool-1 functions as an essential regulatory node for EGFreceptor- and Src-mediated cell growth , 2006, Nature Cell Biology.

[6]  I. Dikic,et al.  Cbl escapes Cdc42-mediated inhibition by downregulation of the adaptor molecule βPix , 2006, Oncogene.

[7]  Ivan Dikic,et al.  The Cbl interactome and its functions , 2005, Nature Reviews Molecular Cell Biology.

[8]  W. Langdon,et al.  Loss of c‐Cbl RING finger function results in high‐intensity TCR signaling and thymic deletion , 2005, The EMBO journal.

[9]  Chunaram Choudhary,et al.  AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations. , 2005, Blood.

[10]  R. Tikkanen,et al.  Oncogenic breakdowns in endocytic adaptor proteins , 2005, FEBS letters.

[11]  W. Langdon,et al.  Mini ReviewNegative regulation of PTK signalling by Cbl proteins , 2005, Growth factors.

[12]  Chunaram Choudhary,et al.  Tyrosine Phosphorylation Regulates Maturation of Receptor Tyrosine Kinases , 2005, Molecular and Cellular Biology.

[13]  A. McMahon,et al.  Sprouty1 is a critical regulator of GDNF/RET-mediated kidney induction. , 2005, Developmental cell.

[14]  Jeffrey L. Wrana,et al.  Clathrin- and non-clathrin-mediated endocytic regulation of cell signalling , 2005, Nature Reviews Molecular Cell Biology.

[15]  S. Lipkowitz,et al.  Regulation of stem cell factor receptor signaling by Cbl family proteins (Cbl-b/c-Cbl). , 2005, Blood.

[16]  Lei Duan,et al.  Biochemical Basis for the Requirement of Kinase Activity for Cbl-dependent Ubiquitinylation and Degradation of a Target Tyrosine Kinase* , 2004, Journal of Biological Chemistry.

[17]  H. Stenmark,et al.  Defective downregulation of receptor tyrosine kinases in cancer , 2004, The EMBO journal.

[18]  Lei Duan,et al.  The Cbl family and other ubiquitin ligases: destructive forces in control of antigen receptor signaling. , 2004, Immunity.

[19]  Y. Yarden,et al.  Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases , 2004, Oncogene.

[20]  D. Hicklin,et al.  FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells. , 2004, Blood.

[21]  L. Malerød,et al.  Clathrin-dependent endocytosis. , 2004, The Biochemical journal.

[22]  K. Sada,et al.  Negative regulation of Lyn protein‐tyrosine kinase by c‐Cbl ubiquitin‐protein ligase in FcɛRI‐mediated mast cell activation , 2003 .

[23]  J. Radich,et al.  The role of FLT3 in haematopoietic malignancies , 2003, Nature Reviews Cancer.

[24]  Morag Park,et al.  Escape from Cbl-mediated downregulation: a recurrent theme for oncogenic deregulation of receptor tyrosine kinases. , 2003, Cancer cell.

[25]  Pier Paolo Di Fiore,et al.  Multiple monoubiquitination of RTKs is sufficient for their endocytosis and degradation , 2003, Nature Cell Biology.

[26]  Chunaram Choudhary,et al.  Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. , 2003, Blood.

[27]  J. Borst,et al.  c-Cbl Is Involved in Met Signaling in B Cells and Mediates Hepatocyte Growth Factor-Induced Receptor Ubiquitination , 2002, The Journal of Immunology.

[28]  J. Griffin,et al.  The roles of FLT3 in hematopoiesis and leukemia. , 2002, Blood.

[29]  G. Ehninger,et al.  Analysis of Flt3-activating Mutations in 979 Patients with Acute Myelogenous Leukemia: Association with Fab Subtypes and Identification of Subgroups with Poor Prognosis , 2022 .

[30]  Hugo J Bellen,et al.  When cell biology meets development: endocytic regulation of signaling pathways. , 2002, Genes & development.

[31]  I. Dikic,et al.  Cbl–CIN85–endophilin complex mediates ligand-induced downregulation of EGF receptors , 2002, Nature.

[32]  Giorgio F. Gilestro,et al.  The endophilin–CIN85–Cbl complex mediates ligand-dependent downregulation of c-Met , 2002, Nature.

[33]  H. Band,et al.  Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. , 2001, Molecular cell.

[34]  M. K. Magnússon,et al.  Rabaptin-5 is a novel fusion partner to platelet-derived growth factor beta receptor in chronic myelomonocytic leukemia. , 2001, Blood.

[35]  T. Hunter,et al.  Oncogenic kinase signalling , 2001, Nature.

[36]  Morag Park,et al.  The receptor tyrosine kinases: role in cancer progression. , 2001, Surgical oncology clinics of North America.

[37]  W. Langdon,et al.  Cbl: many adaptations to regulate protein tyrosine kinases , 2001, Nature Reviews Molecular Cell Biology.

[38]  W. Langdon,et al.  Suppression of Apoptosis Induced by Growth Factor Withdrawal by an Oncogenic Form of c-Cbl* , 2001, The Journal of Biological Chemistry.

[39]  Y. Yarden,et al.  Molecular mechanisms underlying endocytosis and sorting of ErbB receptor tyrosine kinases , 2001, FEBS letters.

[40]  F. Walker,et al.  RING finger mutations that abolish c-Cbl-directed polyubiquitination and downregulation of the EGF receptor are insufficient for cell transformation. , 2001, Molecular cell.

[41]  R. Ganju,et al.  SHP2 and cbl participate in alpha-chemokine receptor CXCR4-mediated signaling pathways. , 2001, Blood.

[42]  J. Bos,et al.  Activation of the Ras‐related GTPase Rap1 by thymocyte TCR engagement and during selection , 2000, European journal of immunology.

[43]  Ping Wang,et al.  Structure of a c-Cbl–UbcH7 Complex RING Domain Function in Ubiquitin-Protein Ligases , 2000, Cell.

[44]  S. Schmid,et al.  Regulation of signal transduction by endocytosis. , 2000, Current opinion in cell biology.

[45]  W. Berdel,et al.  Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. , 2000, Blood.

[46]  A Ciechanover,et al.  Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. , 1999, Molecular cell.

[47]  T. Hunter,et al.  The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase. , 1999, Science.

[48]  Y. Yarden,et al.  The RING Finger of c-Cbl Mediates Desensitization of the Epidermal Growth Factor Receptor* , 1999, The Journal of Biological Chemistry.

[49]  W. Hiddemann,et al.  Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. , 1999, Blood.

[50]  Michael J. Eck,et al.  Structure of the amino-terminal domain of Cbl complexed to its binding site on ZAP-70 kinase , 1999, Nature.

[51]  D. Birnbaum,et al.  FLT3 signaling in hematopoietic cells involves CBL, SHC and an unknown P115 as prominent tyrosine-phosphorylated substrates , 1998, Leukemia.

[52]  W. Langdon,et al.  Tyrosine kinase activity of the EGF receptor is enhanced by the expression of oncogenic 70Z-Cbl , 1997, Oncogene.

[53]  H. Band,et al.  Phosphotyrosine binding domain-dependent upregulation of the platelet-derived growth factor receptor alpha signaling cascade by transforming mutants of Cbl: implications for Cbl's function and oncogenicity , 1997, Molecular and cellular biology.

[54]  W. Langdon,et al.  EGF receptor binding and transformation by v-cbl is ablated by the introduction of a loss-of-function mutation from the Caenorhabditis elegans sli-1 gene , 1997, Oncogene.

[55]  P. Dentelli,et al.  Discrete protein interactions with the Grb2/c-Cbl complex in SCF- and TPO-mediated myeloid cell proliferation. , 1996, Oncogene.

[56]  W. Langdon,et al.  Tumour induction by activated abl involves tyrosine phosphorylation of the product of the cbl oncogene. , 1994, The EMBO journal.

[57]  M. Ratajczak,et al.  STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[58]  D. Pardoll,et al.  A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations , 1991, Cell.

[59]  S. Klinken,et al.  v-cbl, an oncogene from a dual-recombinant murine retrovirus that induces early B-lineage lymphomas. , 1989, Proceedings of the National Academy of Sciences of the United States of America.